Do you ever withhold adjuvant RT after BCS in older women with stage I triple positive/Luminal-Her2 subtype breast cancers?  

Her2 status was not evaluated as part of the PRIME 2 or CALGB trials and luminal Her2 patients likely represent a small minority of those enrolled in these trials, so how applicable are these data to such patients? 



Answer from: Radiation Oncologist at Academic Institution